Table 2 Evaluation and comparison of drug resistance rate of anti-tuberculosis drugs in 2014–2019

 Any drug-resistance

95 (42.6)

85 (49.7)

60 (56.1)

96 (50.5)

127 (38.4)

195 (42.2)

658 (44.3)

16.820

0.005

 INH

71 (31.8)

67 (39.2)

42 (39.3)

68 (35.8)

85 (25.7)

132 (28.6)

465 (31.3)

16.349

0.006

 RIF

60 (26.9)

63 (36.8)

48 (44.9)

68 (35.8)

86 (26.0)

136 (29.4)

461 (31.1)

20.521

0.001

 EMB

23 (10.3)

12 (7.0)

20 (18.7)

26 (13.7)

26 (7.9)

41 (8.9)

148 (10.0)

15.941

0.007

 STR

48 (21.5)

39 (22.8)

24 (22.4)

50 (26.3)

56 (16.9)

98 (21.2)

315 (21.2)

6.977

0.222

 MDR

54 (24.2)

50 (29.2)

38 (35.5)

53 (27.9)

63 (19.0)

111 (24.0)

369 (24.9)

15.430

0.009

 Any second-line drug resistance

42 (18.8)

43 (25.1)

34 (31.8)

46 (24.2)

47 (14.2)

96 (20.8)

308 (20.8)

20.435

0.001

 CPM

2 (0.9)

3 (1.8)

3 (2.8)

7 (3.7)

6 (1.8)

21 (4.5)

42 (2.8)

10.443

0.064

 KAR

6 (2.7)

5 (2.9)

7 (6.5)

13 (6.8)

6 (1.8)

14 (3.0)

51 (3.4)

13.119

0.022

 OFX

38 (17.0)

41 (24.0)

33 (30.8)

42 (22.1)

43 (13.0)

76 (16.5)

273 (18.4)

24.208

< 0.001

 PTO

1 (0.4)

1 (0.6)

0 (0.0)

0 (0.0)

0 (0.0)

18 (3.9)

20 (1.3)

34.796

< 0.001

 XDR

4 (1.8)

3 (1.8)

5 (4.7)

10 (5.3)

4 (1.2)

7 (1.5)

33 (2.2)

11.580

0.041

 Any drug-resistance

35 (28.0)

22 (25.0)

13 (33.3)

29 (30.9)

47 (24.0)

67 (23.7)

213 (25.8)

3.759

0.585

 INH

22 (17.6)

14 (15.9)

6 (15.4)

17 (18.1)

27 (13.8)

36 (12.7)

122 (14.8)

2.813

0.729

 RIF

15 (12.0)

8 (9.1)

7 (17.9)

13 (13.8)

23 (11.7)

28 (9.9)

94 (11.4)

3.181

0.672

 EMB

6 (4.8)

2 (2.3)

1 (2.6)

4 (4.3)

6 (3.1)

11 (3.9)

30 (3.6)

1.462

0.917

 STR

17 (13.6)

9 (10.2)

6 (15.4)

13 (13.8)

25 (12.8)

31 (11.0)

101 (12.2)

1.604

0.901

 MDR

14 (11.2)

4 (4.5)

5 (12.8)

8 (8.5)

15 (7.7)

25 (8.8)

71 (8.6)

4.210

0.520

 Any second-line drug resistance

13 (10.4)

7 (8.0)

7 (17.9)

11 (11.7)

12 (6.1)

26 (9.2)

76 (9.2)

6.397

0.270

 CPM

1 (0.8)

1 (1.1)

0 (0.0)

3 (3.2)

3 (1.5)

7 (2.5)

15 (1.8)

4.133

0.530

 KAR

2 (1.6)

1 (1.1)

0 (0.0)

4 (4.3)

1 (0.5)

6 (2.1)

14 (1.7)

6.696

0.244

 OFX

10 (8.0)

7 (8.0)

7 (17.9)

8 (8.5)

10 (5.1)

17 (6.0)

59 (7.2)

7.388

0.193

 PTO

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

2 (0.7)

2 (0.2)

4.289

0.509

 XDR

0 (0.0)

1 (1.1)

0 (0.0)

1 (1.1)

0 (0.0)

1 (0.4)

3 (0.4)

4.383

0.496

 Any drug-resistance

60 (61.2)

63 (75.9)

47 (69.1)

67 (69.8)

80 (59.3)

128 (71.5)

445 (67.5)

10.236

0.069

 INH

49 (50.0)

53 (63.9)

36 (52.9)

51 (53.1)

58 (43.0)

96 (53.6)

343 (52.0)

9.512

0.090

 RIF

45 (45.9)

55 (66.3)

41 (60.3)

55 (57.3)

63 (46.7)

108 (60.3)

367 (55.7)

14.257

0.014

 EMB

17 (17.3)

10 (12.0)

19 (27.9)

22 (22.9)

20 (14.8)

30 (16.8)

118 (17.9)

9.294

0.098

 STR

31 (31.6)

30 (36.1)

18 (26.5)

37 (38.5)

31 (23.0)

67 (37.4)

214 (32.5)

10.845

0.055

 MDR

40 (40.8)

46 (55.4)

33 (48.5)

45 (46.9)

48 (35.6)

86 (48.0)

298 (45.2)

10.328

0.066

 Any second-line drug resistance

29 (29.6)

36 (43.4)

27 (39.7)

35 (36.5)

35 (25.9)

70 (39.1)

232 (35.2)

10.741

0.057

 CPM

1 (1.0)

2 (2.4)

3 (4.4)

4 (4.2)

3 (2.2)

14 (7.8)

27 (4.1)

10.541

0.061

 KAR

4 (4.1)

4 (4.8)

7 (10.3)

9 (9.4)

5 (3.7)

8 (4.5)

37 (5.6)

6.544

0.257

 OFX

28 (28.6)

34 (41.0)

26 (38.2)

34 (35.4)

33 (24.4)

59 (33.0)

214 (32.5)

8.806

0.117

 PTO

1 (1.0)

1 (1.2)

0 (0.0)

0 (0.0)

0 (0.0)

16 (8.9)

18 (2.7)

35.332

< 0.001

 XDR

4 (4.1)

2 (2.4)

5 (7.4)

9 (9.4)

4 (3.0)

6 (3.4)

30 (4.6)

7.670

0.175